C8 Health vs MyoVista wavECG
HeartSciences' MyoVista wavECG, a 12-lead resting ECG with advisory interpretive statements for adults and children, received 510(k) K260005 on October 5, 2026 without the company's AI-ECG algorithm. HeartSciences says it does not intend to commercialize the device without a cleared algorithm and gives no timeline, and its site says the AI-ECG products are not commercially available in the United States. A cardiology clinic evaluating ECG devices can follow it, and the homepage links an Epic showroom listing. The company also announced a business combination with Fortitude Mining Holdings, owned by Digital Currency Group, in June 2026, with closing expected in the fourth quarter.
C8 Health was founded at Geneva University Hospital in 2019 and is sold to health systems as a platform built around a hospital's vetted knowledge and quality metrics for frontline clinicians. The vendor makes no FDA claim and says integration needs a light lift from internal IT teams.
Decision support · Reviewed November 2, 2026
C8 Health
by C8 Health Inc. · founded 2019
Protocol knowledge platform for hospitals, with an AI assistant that answers only from the hospital's vetted content.
MyoVista wavECG
by HeartSciences
12-lead resting ECG device for cardiology clinics, FDA 510(k) cleared in October 2026 without its AI-ECG algorithm.
When to pick each one
C8 Health
- Founded at Geneva University Hospital in 2019
- Vendor says integration needs a light lift
MyoVista wavECG
- 12-lead resting ECG cleared, K260005
- Cleared without the AI-ECG algorithm
- Epic showroom listing
Score
Each row shows points earned of points available under the published rubric.
C8 Health
32of 100
MyoVista wavECG
31of 100
| Dimension | C8 Health | MyoVista wavECG | Difference |
|---|---|---|---|
| FDA clearance | 0 / 12 | 12 / 12 | -12 |
| HIPAA / SOC2 / BAA | 10 / 10 | 6 / 10 | +4 |
| EHR integrations (count) | 0 / 5.6 | 1.7 / 5.6 | -1.7 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 1.9 / 4.8 | -1.9 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 8.4 / 21 | 0 / 21 | +8.4 |
| RCT / meta-analysis / systematic review | 0 / 9 | 0 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 4.2 / 6 | 0 / 6 | +4.2 |
Scroll horizontally to see every column.
Pricing
C8 Health
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
MyoVista wavECG
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
C8 Health
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names C8 Health.
MyoVista wavECG
FDA decisions
K260005 (opens in new tab)510(k)2026-10-05
MyoVista wavECG (DG-200-B15-003)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | C8 Health | MyoVista wavECG |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Epic |
| Founded | 2019 | n/a |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.